The phrase “
data integrity”
seems to be everywhere. It is used in a number of places and
situations, and the FDA has its own definition of the term. At its
plainest, data integrity is defined as the assurance that data is
complete, consistent and accurate. FDA requires this data to be
attributable, legible, contemporaneously recorded, to be an original or a
true copy, and to be accurate. This criterion is embodied in the
acronym ALCOA.
Is just an understanding of this definition
sufficient? In order to understand data integrity from the computerized
systems point of view; one has to apply
21 CFR Part 11 and Annex 11
to data. Its implementation is considered difficult for a number of
reasons. To apply data integrity to computer systems, one needs to
understand the concept of data integrity.
Understanding is necessary in view of the FDA’s stepped up inspections
It
is only this basic understanding that will help to determine what needs
to be done to meet national and global data integrity requirements.
This is all the more important in view of the fact that regulatory
agencies such as the FDA have accelerated inspections related to data
integrity, as a result of which there has been a big rise in the number
of citations relating to data integrity.
When it comes to data
integrity for computerized systems, the requirements set out in 21 CFR
Part 11 and Annex 11 need to be kept in mind from the following
perspectives:
o The background to and the way in which 21 CFR
Part 11 and Annex 11 have evolved and why they are being talked about
all over again
o An understanding of the full overview of Part 11 and Annex 11 and their key requirements
o Clear
understanding of how the use of Risk Based Assessment will not only
achieve data integrity and compliance but also bring down work
considerably
o The FDA’s and other regulatory authorities’ method of inspecting computerized systems for data integrity.
A complete two-day exploration of data integrity from the FDA’s perspective
It
is to familiarize IT professionals and professionals who work on data
integrity that GlobalCompliancePanel, a leading provider of professional
trainings for the areas of regulatory compliance will be organizing a
two-day seminar.
The Director of this seminar is Angela Bazigos,
who is CEO of Touchstone Technologies Silicon Valley. Angela brings over
40 years in the healthcare and life sciences industries. To gain the
benefit of Angela’s experience in the industry and to discover ways of
ensuring data integrity in the computer systems of a number of
healthcare and life sciences disciplines, please register for this
seminar by visiting
http://www.globalcompliancepanel.com/control/globalseminars/~product_id=900946SEMINAR?wordpress_SEO
. This course has been pre-approved by RAPS as eligible for up to 12
credits towards a participant's RAC recertification upon full
completion.
Practical understanding of data integrity
This
seminar is very hands-on and is meant to offer guidance on how to
ensure data integrity in highly regulated industries. It is of relevance
and importance to both beginners and experienced professionals alike.
She will offer a completely detailed experience of validation and 21 CFR
Part 11 compliance that a computer system needs to have.
One of
the major takeaways of this seminar is the templates Angela will give to
participants, which will help them build a full package for meeting
data integrity for computerized systems. She will also detail the
activities associated with Computer Systems Validation, exploring areas
such as:
o
What is Data Integrity and how is it implemented
o How to use Risk Based Assessments to reduce work while still achieving Data Integrity and Compliance?
o Data Integrity Frequently Asked Questions
o
Validation Master Plan
o Risk Based Assessment
o Complete Validation for a System (software development lifecycle)
o Automated Test Tools
o Infrastructure Requirements
o Change Control
o SOPs.
https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf